BIO:ON Insight #6 · Jun 30, 2026
A wall around solid tumours falls, immunity gets a reset, and a pill takes aim at the injection
China approves the world's first CAR-T for a solid tumour, Moderna unveils an in vivo CAR-T for lupus, and Corxel's oral GLP-1 shows competitive weight loss in Phase 2. How long does "impossible" last in medicine?
What I learned this week
If I had to sum up this week in one word, I'd pick access. The question used to be "is this even possible?" Now it's becoming "how many people can it reach, at what cost, and how fast?" That's why it was so interesting to see a very expensive cell therapy win a historic approval in the same week as attempts to get there with one injection or one pill. See you next issue. 🙏
Yaehyun Lee · Quoted from the Editor's Insight I wrote for this issue.
Stories in this issue
- FDA Approvals
World's first solid-tumour CAR-T: CARsgen's satri-cel approved in China
CARsgensatricabtagene autoleucelChina NMPA
- Pipeline Analysis
Moderna unveils mRNA-6007, an in vivo CAR-T programme for autoimmunity
Moderna
- Clinical Trials
Corxel's oral GLP-1 candidate succeeds in Phase 2
Corxel
AI summary
- 1China's NMPA approved CARsgen's gastric cancer CAR-T satri-cel — the world's first CAR-T for a solid tumor.
- 2Moderna unveiled mRNA-6007, an in vivo CAR-T that removes lupus B cells inside the body.
- 3Corxel's oral GLP-1 candidate showed competitive weight loss in Phase 2.
Relevant rolesR&DRegulatory affairsClinical development
Summary and tags generated by AI from the issue text.
References
- 1.World's first solid-tumour CAR-T approval — CARsgen's satri-cel approved by NMPA (opens in a new tab)
Fierce Pharma, Jun 24, 2026
- 2.Moderna unveils mRNA-6007 in vivo CAR-T for autoimmune disease (opens in a new tab)
Fierce Biotech, Jun 26, 2026
- 3.Corxel's oral GLP-1 candidate succeeds in Phase 2 (opens in a new tab)
Fierce Biotech, Jun 23, 2026
Related insights
Other issues covering the same companies, drugs or topics